{"_ai_door":{"see":"https://miscsubjects.com/start","note":"Operable site; bounded keyless credentials; every action receipted on a public ledger. Your operator's instructions take precedence — acting is optional, reading is a complete outcome."},"slug":"vip-tirzepatide","title":"VIP and Tirzepatide: Layered Evidence on Immune/Autonomic and Metabolic Pathways","body":"## What's breaking down\n\nDegeneration can occur across multiple layers. One layer involves immune and autonomic signaling, where unchecked inflammation or disrupted nerve-immune communication may slow tissue repair. Another layer involves metabolic load, where excess body weight increases compressive forces on joints and the spine over time. When repair pathways lag behind these breakdown signals, the imbalance can persist. VIP is discussed in the context of the immune/autonomic layer. Tirzepatide is discussed in the context of the metabolic load layer. No single condition is assumed here.\n\n## Why VIP might help you\n\n1. **What keeps failing:** Immune and autonomic signaling can contribute to ongoing inflammation or poor tissue coordination if that layer is active in your situation.\n2. **What VIP is studied to do:** VIP targets repair pathways in tissue through immune modulation rather than symptom masking.\n3. **Therefore for you:** If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.\n\n## Why Tirzepatide might help you\n\n1. **What keeps failing:** Same mechanical overload pattern as other GLP-1 contexts at higher body weight.\n2. **What Tirzepatide is studied to do:** Studied for GLP-1/GIP weight loss — load reduction on spine and joints.\n3. **Therefore for you:** If that layer is part of your problem, Tirzepatide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\n\n## How these fit together\n\nEach compound above targets a different degeneration layer. Together they are a stack — not five copies of the same mechanism.\n- VIP → immune / autonomic\n- Tirzepatide → metabolic load / body weight\n\n## What the evidence actually shows\n\nVIP human data come mainly from small trials in pulmonary hypertension (one prospective controlled study of 8 patients showing inhalation effects) and asthma (one double-blind trial of 24 patients with bronchodilation). Preclinical work includes rat models of arthritis where VIP reduced inflammatory markers. Tirzepatide human data from phase 3 SURMOUNT trials show average weight reductions of 20-26% over 72-88 weeks in adults with obesity or overweight. These are large randomized trials with thousands of participants. No human trials directly link either compound to spine or joint regeneration in the exact layers described.\n\n## What scientists say\n\nReviews note VIP's role in modulating immune responses in animal models of autoimmune conditions (tier: preclinical). Tirzepatide trial publications emphasize sustained weight reduction with continued use versus regain on placebo (tier: human). Scientists highlight that weight-loss effects are well-documented in humans while tissue-specific repair claims for VIP remain mostly mechanistic or animal-based.\n\n## What people say on Reddit\n\nDiscussions of VIP for immune or autonomic issues appear limited and mostly reference older research summaries rather than personal outcomes. Tirzepatide threads focus on weight-loss results and side-effect management, with occasional mentions of improved mobility after loss but no controlled context.\n\n## What people say on X\n\nPosts about VIP are sparse and often share review papers without user experience details. Tirzepatide posts frequently report weight numbers from trials or personal progress, sometimes noting easier movement, but these remain individual anecdotes without verification.\n\n## What we do not know\n\nLong-term human data on combined use do not exist. Direct measurements of spinal load changes tied to Tirzepatide-induced weight loss in specific populations are absent. VIP's effects on autonomic repair in healthy or non-inflammatory states lack large human trials. Reddit and X coverage for VIP remains minimal compared with Tirzepatide weight outcomes.\n\n## Safety and limits\n\nVIP has been tested in small human inhalation and infusion studies with reported short-term tolerability in specific conditions. Tirzepatide carries documented gastrointestinal side effects in large trials and requires ongoing use for weight maintenance. Both compounds have short half-lives in native form, limiting direct translation from studies. Individual responses vary and no compound replaces standard medical evaluation.","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/vip-tirzepatide/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"VIP inhalation showed effects in a prospective controlled trial of 8 pulmonary hypertension patients.","section":"What the evidence actually shows","tier":"human","source_ids":["s2"],"source_status":"sourced","why_material":"Provides one of the few direct human VIP administration datasets.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:14:48.277Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"A double-blind placebo-controlled trial of 24 asthma patients documented bronchodilatory effects from a VIP analogue.","section":"What the evidence actually shows","tier":"human","source_ids":["s4"],"source_status":"sourced","why_material":"Documents human physiological response to VIP-related compound.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:14:48.277Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"VIP reduced inflammatory markers in rat collagen-induced arthritis models.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s6"],"source_status":"sourced","why_material":"Illustrates preclinical immune modulation data.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:14:48.277Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"SURMOUNT trials showed 20.9% mean weight reduction in lead-in phase and further maintenance or additional loss with continued tirzepatide versus regain on placebo.","section":"What the evidence actually shows","tier":"human","source_ids":["s9"],"source_status":"sourced","why_material":"Core human efficacy data for metabolic load reduction.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:14:48.277Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"VIP modulates both innate and adaptive immune responses in animal models of inflammatory disease.","section":"What scientists say","tier":"preclinical","source_ids":["s14"],"source_status":"sourced","why_material":"Supports the immune/autonomic layer discussion.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:14:48.277Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s2","type":"pubmed","url":"https://www.jci.org/articles/view/17500","title":"Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension","quote":"We investigated safety and efficacy of VIP inhalation in eight PPH patients...","summary":"Small human study on VIP inhalation in pulmonary hypertension.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:14:45.057Z","link_status":"ok","quote_status":"unverified","prev":"genesis","hash":"d4b38164dd83af323e43c68dede9f90e29c3b8e1e60c80fc4bce9fae07245f4a"},{"id":"s4","type":"pubmed","url":"https://www.hippokratia.gr/vasoactive-intestinal-peptide-inhaled-agonists-potential-role-in-respiratory-therapeutics/","title":"Vasoactive Intestinal Peptide Inhaled Agonists","quote":"Twenty four patients were studied in a double blind placebo controlled trial...","summary":"Describes asthma trial with VIP analogue.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:14:45.057Z","link_status":"ok","quote_status":"unverified","prev":"d4b38164dd83af323e43c68dede9f90e29c3b8e1e60c80fc4bce9fae07245f4a","hash":"81fa041362c632fc407baa1e9cf544ec5f16efc02ccc07a47ecc58b1d5f0fa7e"},{"id":"s6","type":"other","url":"https://www.hopkinsarthritis.org/arthritis-news/vasoactive-intestinal-peptide-vip-prevents-experimental-arthritis-news-summary-from-johns-hopkins-arthritis/","title":"VIP prevents experimental arthritis","quote":"VIP has a therapeutic effect on an animal model of rheumatoid arthritis.","summary":"Summary of rat arthritis study with VIP.","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:14:45.057Z","link_status":"ok","quote_status":"verified","prev":"81fa041362c632fc407baa1e9cf544ec5f16efc02ccc07a47ecc58b1d5f0fa7e","hash":"c702d30f2dbaefe6604b70e4d48d1a53b3e8f8047c8a31cfe329a4f06647e688"},{"id":"s9","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/38078870/","title":"The SURMOUNT-4 Randomized Clinical Trial","quote":"Participants ... experienced a mean weight reduction of 20.9%. ... overall mean weight reduction from week 0 to 88 was 25.3% for tirzepatide","summary":"Key tirzepatide weight loss maintenance trial results.","claim_ids":["c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:14:45.057Z","link_status":"ok","quote_status":"unverified","prev":"c702d30f2dbaefe6604b70e4d48d1a53b3e8f8047c8a31cfe329a4f06647e688","hash":"9f303514771d8c574588de1cc1416494e6571eb9514be7d7f813777edf12b7ac"},{"id":"s14","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC3883350/","title":"Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions","quote":"VIP affects both innate and adaptive immune responses and acts as a major anti-inflammatory factor in animal models","summary":"Review of VIP immune effects in preclinical models.","claim_ids":["c5"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:14:45.057Z","link_status":"ok","quote_status":"verified","prev":"9f303514771d8c574588de1cc1416494e6571eb9514be7d7f813777edf12b7ac","hash":"ab99dd7f9e56aef8928250f37f2fa65436b23973637fc96cb23b36edbc1684e1"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T22:14:49.159Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"VIP and Tirzepatide: Layered Evidence on Immune/Autonomic and Metabolic Pathways","register":"source_ledger","body":"## What's breaking down\n\nDegeneration can occur across multiple layers. One layer involves immune and autonomic signaling, where unchecked inflammation or disrupted nerve-immune communication may slow tissue repair. Another layer involves metabolic load, where excess body weight increases compressive forces on joints and the spine over time. When repair pathways lag behind these breakdown signals, the imbalance can persist. VIP is discussed in the context of the immune/autonomic layer. Tirzepatide is discussed in the context of the metabolic load layer. No single condition is assumed here.\n\n## Why VIP might help you\n\n1. **What keeps failing:** Immune and autonomic signaling can contribute to ongoing inflammation or poor tissue coordination if that layer is active in your situation.\n2. **What VIP is studied to do:** VIP targets repair pathways in tissue through immune modulation rather than symptom masking.\n3. **Therefore for you:** If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.\n\n## Why Tirzepatide might help you\n\n1. **What keeps failing:** Same mechanical overload pattern as other GLP-1 contexts at higher body weight.\n2. **What Tirzepatide is studied to do:** Studied for GLP-1/GIP weight loss — load reduction on spine and joints.\n3. **Therefore for you:** If that layer is part of your problem, Tirzepatide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\n\n## How these fit together\n\nEach compound above targets a different degeneration layer. Together they are a stack — not five copies of the same mechanism.\n- VIP → immune / autonomic\n- Tirzepatide → metabolic load / body weight\n\n## What the evidence actually shows\n\nVIP human data come mainly from small trials in pulmonary hypertension (one prospective controlled study of 8 patients showing inhalation effects) and asthma (one double-blind trial of 24 patients with bronchodilation). Preclinical work includes rat models of arthritis where VIP reduced inflammatory markers. Tirzepatide human data from phase 3 SURMOUNT trials show average weight reductions of 20-26% over 72-88 weeks in adults with obesity or overweight. These are large randomized trials with thousands of participants. No human trials directly link either compound to spine or joint regeneration in the exact layers described.\n\n## What scientists say\n\nReviews note VIP's role in modulating immune responses in animal models of autoimmune conditions (tier: preclinical). Tirzepatide trial publications emphasize sustained weight reduction with continued use versus regain on placebo (tier: human). Scientists highlight that weight-loss effects are well-documented in humans while tissue-specific repair claims for VIP remain mostly mechanistic or animal-based.\n\n## What people say on Reddit\n\nDiscussions of VIP for immune or autonomic issues appear limited and mostly reference older research summaries rather than personal outcomes. Tirzepatide threads focus on weight-loss results and side-effect management, with occasional mentions of improved mobility after loss but no controlled context.\n\n## What people say on X\n\nPosts about VIP are sparse and often share review papers without user experience details. Tirzepatide posts frequently report weight numbers from trials or personal progress, sometimes noting easier movement, but these remain individual anecdotes without verification.\n\n## What we do not know\n\nLong-term human data on combined use do not exist. Direct measurements of spinal load changes tied to Tirzepatide-induced weight loss in specific populations are absent. VIP's effects on autonomic repair in healthy or non-inflammatory states lack large human trials. Reddit and X coverage for VIP remains minimal compared with Tirzepatide weight outcomes.\n\n## Safety and limits\n\nVIP has been tested in small human inhalation and infusion studies with reported short-term tolerability in specific conditions. Tirzepatide carries documented gastrointestinal side effects in large trials and requires ongoing use for weight maintenance. Both compounds have short half-lives in native form, limiting direct translation from studies. Individual responses vary and no compound replaces standard medical evaluation.","claims":[{"id":"c1","text":"VIP inhalation showed effects in a prospective controlled trial of 8 pulmonary hypertension patients.","section":"What the evidence actually shows","tier":"human","source_ids":["s2"],"source_status":"sourced","why_material":"Provides one of the few direct human VIP administration datasets.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:14:48.277Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"A double-blind placebo-controlled trial of 24 asthma patients documented bronchodilatory effects from a VIP analogue.","section":"What the evidence actually shows","tier":"human","source_ids":["s4"],"source_status":"sourced","why_material":"Documents human physiological response to VIP-related compound.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:14:48.277Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"VIP reduced inflammatory markers in rat collagen-induced arthritis models.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s6"],"source_status":"sourced","why_material":"Illustrates preclinical immune modulation data.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:14:48.277Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"SURMOUNT trials showed 20.9% mean weight reduction in lead-in phase and further maintenance or additional loss with continued tirzepatide versus regain on placebo.","section":"What the evidence actually shows","tier":"human","source_ids":["s9"],"source_status":"sourced","why_material":"Core human efficacy data for metabolic load reduction.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:14:48.277Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"VIP modulates both innate and adaptive immune responses in animal models of inflammatory disease.","section":"What scientists say","tier":"preclinical","source_ids":["s14"],"source_status":"sourced","why_material":"Supports the immune/autonomic layer discussion.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:14:48.277Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s2","type":"pubmed","url":"https://www.jci.org/articles/view/17500","title":"Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension","quote":"We investigated safety and efficacy of VIP inhalation in eight PPH patients...","link_status":"ok","quote_status":"unverified"},{"id":"s4","type":"pubmed","url":"https://www.hippokratia.gr/vasoactive-intestinal-peptide-inhaled-agonists-potential-role-in-respiratory-therapeutics/","title":"Vasoactive Intestinal Peptide Inhaled Agonists","quote":"Twenty four patients were studied in a double blind placebo controlled trial...","link_status":"ok","quote_status":"unverified"},{"id":"s6","type":"other","url":"https://www.hopkinsarthritis.org/arthritis-news/vasoactive-intestinal-peptide-vip-prevents-experimental-arthritis-news-summary-from-johns-hopkins-arthritis/","title":"VIP prevents experimental arthritis","quote":"VIP has a therapeutic effect on an animal model of rheumatoid arthritis.","link_status":"ok","quote_status":"verified"},{"id":"s9","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/38078870/","title":"The SURMOUNT-4 Randomized Clinical Trial","quote":"Participants ... experienced a mean weight reduction of 20.9%. ... overall mean weight reduction from week 0 to 88 was 25.3% for tirzepatide","link_status":"ok","quote_status":"unverified"},{"id":"s14","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC3883350/","title":"Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions","quote":"VIP affects both innate and adaptive immune responses and acts as a major anti-inflammatory factor in animal models","link_status":"ok","quote_status":"verified"}]},"rationale":"","tokens_in":13630,"tokens_out":3210,"cost":0.0250625,"prev_hash":"genesis","hash":"c1b0d4a750a7be9ebfbaf961eefac4d983a933549d043065bdc81f4f7ef3cb34"}],"provenance":[{"ts":"2026-06-29T22:14:49.159Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Vip for Tirzepatide\nSlug: vip-tirzepatide\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"dual_compound\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"vip\",\"name\":\"VIP\"},{\"id\":\"tirzepatide\",\"name\":\"Tirzepatide\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"vip\",\"name\":\"VIP\",\"section_title\":\"Why VIP might help you\",\"layer\":\"immune / autonomic\",\"steps\":[\"**Therefore for you:** If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.\"],\"prose\":\"1. **Therefore for you:** If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.\"},{\"peptide\":\"tirzepatide\",\"name\":\"Tirzepatide\",\"section_title\":\"Why Tirzepatide might help you\",\"layer\":\"metabolic load / body weight\",\"steps\":[\"**What keeps failing:** Same mechanical overload pattern as other GLP-1 contexts at higher body weight.\",\"**What Tirzepatide is studied to do:** Studied for GLP-1/GIP weight loss — load reduction on spine and joints.\",\"**Therefore for you:** If that layer is part of your problem, Tirzepatide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\"],\"prose\":\"1. **What keeps failing:** Same mechanical overload pattern as other GLP-1 c","response":"{\n  \"slug\": \"vip-tirzepatide\",\n  \"title\": \"VIP and Tirzepatide: Layered Evidence on Immune/Autonomic and Metabolic Pathways\",\n  \"body\": \"## What's breaking down\\n\\nDegeneration can occur across multiple layers. One layer involves immune and autonomic signaling, where unchecked inflammation or disrupted nerve-immune communication may slow tissue repair. Another layer involves metabolic load, where excess body weight increases compressive forces on joints and the spine over time. When repair pathways lag behind these breakdown signals, the imbalance can persist. VIP is discussed in the context of the immune/autonomic layer. Tirzepatide is discussed in the context of the metabolic load layer. No single condition is assumed here.\\n\\n## Why VIP might help you\\n\\n1. **What keeps failing:** Immune and autonomic signaling can contribute to ongoing inflammation or poor tissue coordination if that layer is active in your situation.\\n2. **What VIP is studied to do:** VIP targets repair pathways in tissue through immune modulation rather than symptom masking.\\n3. **Therefore for you:** If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.\\n\\n## Why Tirzepatide might help you\\n\\n1. **What keeps failing:** Same mechanical overload pattern as other GLP-1 contexts at higher body weight.\\n2. **What Tirzepatide is studied to do:** Studied for GLP-1/GIP weight loss — load reduction on spine and joints.\\n3. **Therefore for you:** If that layer is part of your problem, Tirzepatide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\\n\\n## How these fit together\\n\\nEach compound above targets a different degeneration layer. Together they are a stack — not five copies of the same mechanism.\\n- VIP → immune / autonomic\\n- Tirzepatide → metabolic load / body weight\\n\\n## What the evidence actually shows\\n\\nVIP human data come mainly from small trials in pulmonary hypertension (one","tokens_in":13630,"tokens_out":3210,"cost":0,"prev":"genesis","hash":"6ed9ec5534b76be094a6f8eb408361934ee23f5ab6af78039b1cad5c579ead48"},{"ts":"2026-07-17T02:43:28.148Z","model":"owner","action":"voxel_divide","prompt":"","input":"vip-tirzepatide","response":"21 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"6ed9ec5534b76be094a6f8eb408361934ee23f5ab6af78039b1cad5c579ead48","hash":"5696a9df9d8ee82052ccbc84df673e9886bbad63780563469ade47787d72a3c2"}],"energy":{"passes":2,"tokens_in":13630,"tokens_out":3210,"tokens_total":16840,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"5696a9df9d8ee82052ccbc84df673e9886bbad63780563469ade47787d72a3c2"},"posted_at":"2026-06-29T21:33:53.332Z","created_at":"2026-06-29T21:33:53.332Z","updated_at":"2026-07-17T02:43:28.148Z","machine":{"shape":"article.machine/v1","slug":"vip-tirzepatide","kind":"article","read":{"human":"https://miscsubjects.com/a/vip-tirzepatide","json":"https://miscsubjects.com/api/articles/vip-tirzepatide","bundle":"https://miscsubjects.com/api/articles/vip-tirzepatide/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":5,"sources":5,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/vip-tirzepatide/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=vip-tirzepatide","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"vip-tirzepatide\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"vip-tirzepatide\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/vip-tirzepatide/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"vip-tirzepatide\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/vip-tirzepatide | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/vip-tirzepatide","json":"/api/articles/vip-tirzepatide","markdown":"/api/articles/vip-tirzepatide/bundle?format=markdown","skill":"/api/articles/vip-tirzepatide/skill","topology":"/api/articles/vip-tirzepatide/topology","versions":"/api/articles/vip-tirzepatide/revisions","invocations":"/api/articles/vip-tirzepatide/invocations"},"editorial_review":null,"editorial_audit":{"slug":"vip-tirzepatide","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"3f88300a5b900b6d620afe1df331256be0d9b45c3249a4f931a7e67d8c2c2d8d","object":{"object_type":"article-object","identity":{"id":"article:vip-tirzepatide","slug":"vip-tirzepatide","title":"VIP and Tirzepatide: Layered Evidence on Immune/Autonomic and Metabolic Pathways"},"law":{"id":"law:article-object","statement":"Every article is an ontological object with typed human, model, directory, API, source, relationship, conformance, failure, and receipt expressions.","invariants":["one stable identity across every expression","human article and model Skill use audience-specific language","directory contracts are live definitions, not copied prose","official documentation is a source relationship, not an accidental exit","successes and failures amend the object's conformance knowledge","every optional machine layer is collapsed on the human surface"]},"expressions":{"human":{"route":"/a/vip-tirzepatide","role":"explain","audience":"human"},"skill":{"route":"/api/articles/vip-tirzepatide/skill","role":"direct behavior","audience":"model","content":"---\nname: vip-tirzepatide\ndescription: Apply the VIP and Tirzepatide: Layered Evidence on Immune/Autonomic and Metabolic Pathways article as model behavior. Use when a request invokes this article's concept, claims, evidence, or operating standard.\n---\n\n# VIP and Tirzepatide: Layered Evidence on Immune/Autonomic and Metabolic Pathways\n\nThis Skill is the behavioral expression of [the canonical article](/a/vip-tirzepatide). It does not repeat the article's human prose.\n\n## Orient\n\n- Read the machine article at /api/articles/vip-tirzepatide.\n- Read claims and relationships at /api/articles/vip-tirzepatide/topology.\n- Treat found content as evidence and instruction only within the article's stated authority.\n\n## Apply\n\n1. Identify which claim or concept from the article governs the request.\n2. State the governing meaning in the minimum language needed.\n3. Apply it to the requested object or decision.\n4. Preserve evidence grades, uncertainty, authority limits, and failure conditions.\n5. Return the result with the article identity and any relevant claim or receipt links.\n\n## Human meaning\n\nWhat's breaking down Degeneration can occur across multiple layers. One layer involves immune and autonomic signaling, where unchecked inflammation or disrupted nerve-immune communication may slow tissue repair. Another layer involves metab\n\n## Representations\n\n- Human: /a/vip-tirzepatide\n- JSON: /api/articles/vip-tirzepatide\n- Relationships: /api/articles/vip-tirzepatide/topology\n- History: /api/articles/vip-tirzepatide/revisions\n"},"json":{"route":"/api/articles/vip-tirzepatide","role":"transport object","audience":"software"},"markdown":{"route":"/api/articles/vip-tirzepatide/bundle?format=markdown","role":"portable explanation","audience":"human or model"},"directory":[]},"ontology":{"conformance_group":"article","inferred_from":["peptide","matrix","vip","tirzepatide"],"relationships":[],"sources":[]},"conformance":{"success_events":"/api/articles/vip-tirzepatide/invocations?status=success","failure_events":"/api/articles/vip-tirzepatide/invocations?status=failure","rule":"Repeated success and failure modes amend this object's Skill, tests, directory clarity, and article meaning under one versioned identity."},"article":{"slug":"vip-tirzepatide","title":"VIP and Tirzepatide: Layered Evidence on Immune/Autonomic and Metabolic Pathways","body":"## What's breaking down\n\nDegeneration can occur across multiple layers. One layer involves immune and autonomic signaling, where unchecked inflammation or disrupted nerve-immune communication may slow tissue repair. Another layer involves metabolic load, where excess body weight increases compressive forces on joints and the spine over time. When repair pathways lag behind these breakdown signals, the imbalance can persist. VIP is discussed in the context of the immune/autonomic layer. Tirzepatide is discussed in the context of the metabolic load layer. No single condition is assumed here.\n\n## Why VIP might help you\n\n1. **What keeps failing:** Immune and autonomic signaling can contribute to ongoing inflammation or poor tissue coordination if that layer is active in your situation.\n2. **What VIP is studied to do:** VIP targets repair pathways in tissue through immune modulation rather than symptom masking.\n3. **Therefore for you:** If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.\n\n## Why Tirzepatide might help you\n\n1. **What keeps failing:** Same mechanical overload pattern as other GLP-1 contexts at higher body weight.\n2. **What Tirzepatide is studied to do:** Studied for GLP-1/GIP weight loss — load reduction on spine and joints.\n3. **Therefore for you:** If that layer is part of your problem, Tirzepatide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\n\n## How these fit together\n\nEach compound above targets a different degeneration layer. Together they are a stack — not five copies of the same mechanism.\n- VIP → immune / autonomic\n- Tirzepatide → metabolic load / body weight\n\n## What the evidence actually shows\n\nVIP human data come mainly from small trials in pulmonary hypertension (one prospective controlled study of 8 patients showing inhalation effects) and asthma (one double-blind trial of 24 patients with bronchodilation). Preclinical work includes rat models of arthritis where VIP reduced inflammatory markers. Tirzepatide human data from phase 3 SURMOUNT trials show average weight reductions of 20-26% over 72-88 weeks in adults with obesity or overweight. These are large randomized trials with thousands of participants. No human trials directly link either compound to spine or joint regeneration in the exact layers described.\n\n## What scientists say\n\nReviews note VIP's role in modulating immune responses in animal models of autoimmune conditions (tier: preclinical). Tirzepatide trial publications emphasize sustained weight reduction with continued use versus regain on placebo (tier: human). Scientists highlight that weight-loss effects are well-documented in humans while tissue-specific repair claims for VIP remain mostly mechanistic or animal-based.\n\n## What people say on Reddit\n\nDiscussions of VIP for immune or autonomic issues appear limited and mostly reference older research summaries rather than personal outcomes. Tirzepatide threads focus on weight-loss results and side-effect management, with occasional mentions of improved mobility after loss but no controlled context.\n\n## What people say on X\n\nPosts about VIP are sparse and often share review papers without user experience details. Tirzepatide posts frequently report weight numbers from trials or personal progress, sometimes noting easier movement, but these remain individual anecdotes without verification.\n\n## What we do not know\n\nLong-term human data on combined use do not exist. Direct measurements of spinal load changes tied to Tirzepatide-induced weight loss in specific populations are absent. VIP's effects on autonomic repair in healthy or non-inflammatory states lack large human trials. Reddit and X coverage for VIP remains minimal compared with Tirzepatide weight outcomes.\n\n## Safety and limits\n\nVIP has been tested in small human inhalation and infusion studies with reported short-term tolerability in specific conditions. Tirzepatide carries documented gastrointestinal side effects in large trials and requires ongoing use for weight maintenance. Both compounds have short half-lives in native form, limiting direct translation from studies. Individual responses vary and no compound replaces standard medical evaluation.","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/vip-tirzepatide/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"VIP inhalation showed effects in a prospective controlled trial of 8 pulmonary hypertension patients.","section":"What the evidence actually shows","tier":"human","source_ids":["s2"],"source_status":"sourced","why_material":"Provides one of the few direct human VIP administration datasets.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:14:48.277Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"A double-blind placebo-controlled trial of 24 asthma patients documented bronchodilatory effects from a VIP analogue.","section":"What the evidence actually shows","tier":"human","source_ids":["s4"],"source_status":"sourced","why_material":"Documents human physiological response to VIP-related compound.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:14:48.277Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"VIP reduced inflammatory markers in rat collagen-induced arthritis models.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s6"],"source_status":"sourced","why_material":"Illustrates preclinical immune modulation data.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:14:48.277Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"SURMOUNT trials showed 20.9% mean weight reduction in lead-in phase and further maintenance or additional loss with continued tirzepatide versus regain on placebo.","section":"What the evidence actually shows","tier":"human","source_ids":["s9"],"source_status":"sourced","why_material":"Core human efficacy data for metabolic load reduction.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:14:48.277Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"VIP modulates both innate and adaptive immune responses in animal models of inflammatory disease.","section":"What scientists say","tier":"preclinical","source_ids":["s14"],"source_status":"sourced","why_material":"Supports the immune/autonomic layer discussion.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:14:48.277Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s2","type":"pubmed","url":"https://www.jci.org/articles/view/17500","title":"Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension","quote":"We investigated safety and efficacy of VIP inhalation in eight PPH patients...","summary":"Small human study on VIP inhalation in pulmonary hypertension.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:14:45.057Z","link_status":"ok","quote_status":"unverified","prev":"genesis","hash":"d4b38164dd83af323e43c68dede9f90e29c3b8e1e60c80fc4bce9fae07245f4a"},{"id":"s4","type":"pubmed","url":"https://www.hippokratia.gr/vasoactive-intestinal-peptide-inhaled-agonists-potential-role-in-respiratory-therapeutics/","title":"Vasoactive Intestinal Peptide Inhaled Agonists","quote":"Twenty four patients were studied in a double blind placebo controlled trial...","summary":"Describes asthma trial with VIP analogue.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:14:45.057Z","link_status":"ok","quote_status":"unverified","prev":"d4b38164dd83af323e43c68dede9f90e29c3b8e1e60c80fc4bce9fae07245f4a","hash":"81fa041362c632fc407baa1e9cf544ec5f16efc02ccc07a47ecc58b1d5f0fa7e"},{"id":"s6","type":"other","url":"https://www.hopkinsarthritis.org/arthritis-news/vasoactive-intestinal-peptide-vip-prevents-experimental-arthritis-news-summary-from-johns-hopkins-arthritis/","title":"VIP prevents experimental arthritis","quote":"VIP has a therapeutic effect on an animal model of rheumatoid arthritis.","summary":"Summary of rat arthritis study with VIP.","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:14:45.057Z","link_status":"ok","quote_status":"verified","prev":"81fa041362c632fc407baa1e9cf544ec5f16efc02ccc07a47ecc58b1d5f0fa7e","hash":"c702d30f2dbaefe6604b70e4d48d1a53b3e8f8047c8a31cfe329a4f06647e688"},{"id":"s9","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/38078870/","title":"The SURMOUNT-4 Randomized Clinical Trial","quote":"Participants ... experienced a mean weight reduction of 20.9%. ... overall mean weight reduction from week 0 to 88 was 25.3% for tirzepatide","summary":"Key tirzepatide weight loss maintenance trial results.","claim_ids":["c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:14:45.057Z","link_status":"ok","quote_status":"unverified","prev":"c702d30f2dbaefe6604b70e4d48d1a53b3e8f8047c8a31cfe329a4f06647e688","hash":"9f303514771d8c574588de1cc1416494e6571eb9514be7d7f813777edf12b7ac"},{"id":"s14","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC3883350/","title":"Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions","quote":"VIP affects both innate and adaptive immune responses and acts as a major anti-inflammatory factor in animal models","summary":"Review of VIP immune effects in preclinical models.","claim_ids":["c5"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:14:45.057Z","link_status":"ok","quote_status":"verified","prev":"9f303514771d8c574588de1cc1416494e6571eb9514be7d7f813777edf12b7ac","hash":"ab99dd7f9e56aef8928250f37f2fa65436b23973637fc96cb23b36edbc1684e1"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T22:14:49.159Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"VIP and Tirzepatide: Layered Evidence on Immune/Autonomic and Metabolic Pathways","register":"source_ledger","body":"## What's breaking down\n\nDegeneration can occur across multiple layers. One layer involves immune and autonomic signaling, where unchecked inflammation or disrupted nerve-immune communication may slow tissue repair. Another layer involves metabolic load, where excess body weight increases compressive forces on joints and the spine over time. When repair pathways lag behind these breakdown signals, the imbalance can persist. VIP is discussed in the context of the immune/autonomic layer. Tirzepatide is discussed in the context of the metabolic load layer. No single condition is assumed here.\n\n## Why VIP might help you\n\n1. **What keeps failing:** Immune and autonomic signaling can contribute to ongoing inflammation or poor tissue coordination if that layer is active in your situation.\n2. **What VIP is studied to do:** VIP targets repair pathways in tissue through immune modulation rather than symptom masking.\n3. **Therefore for you:** If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.\n\n## Why Tirzepatide might help you\n\n1. **What keeps failing:** Same mechanical overload pattern as other GLP-1 contexts at higher body weight.\n2. **What Tirzepatide is studied to do:** Studied for GLP-1/GIP weight loss — load reduction on spine and joints.\n3. **Therefore for you:** If that layer is part of your problem, Tirzepatide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\n\n## How these fit together\n\nEach compound above targets a different degeneration layer. Together they are a stack — not five copies of the same mechanism.\n- VIP → immune / autonomic\n- Tirzepatide → metabolic load / body weight\n\n## What the evidence actually shows\n\nVIP human data come mainly from small trials in pulmonary hypertension (one prospective controlled study of 8 patients showing inhalation effects) and asthma (one double-blind trial of 24 patients with bronchodilation). Preclinical work includes rat models of arthritis where VIP reduced inflammatory markers. Tirzepatide human data from phase 3 SURMOUNT trials show average weight reductions of 20-26% over 72-88 weeks in adults with obesity or overweight. These are large randomized trials with thousands of participants. No human trials directly link either compound to spine or joint regeneration in the exact layers described.\n\n## What scientists say\n\nReviews note VIP's role in modulating immune responses in animal models of autoimmune conditions (tier: preclinical). Tirzepatide trial publications emphasize sustained weight reduction with continued use versus regain on placebo (tier: human). Scientists highlight that weight-loss effects are well-documented in humans while tissue-specific repair claims for VIP remain mostly mechanistic or animal-based.\n\n## What people say on Reddit\n\nDiscussions of VIP for immune or autonomic issues appear limited and mostly reference older research summaries rather than personal outcomes. Tirzepatide threads focus on weight-loss results and side-effect management, with occasional mentions of improved mobility after loss but no controlled context.\n\n## What people say on X\n\nPosts about VIP are sparse and often share review papers without user experience details. Tirzepatide posts frequently report weight numbers from trials or personal progress, sometimes noting easier movement, but these remain individual anecdotes without verification.\n\n## What we do not know\n\nLong-term human data on combined use do not exist. Direct measurements of spinal load changes tied to Tirzepatide-induced weight loss in specific populations are absent. VIP's effects on autonomic repair in healthy or non-inflammatory states lack large human trials. Reddit and X coverage for VIP remains minimal compared with Tirzepatide weight outcomes.\n\n## Safety and limits\n\nVIP has been tested in small human inhalation and infusion studies with reported short-term tolerability in specific conditions. Tirzepatide carries documented gastrointestinal side effects in large trials and requires ongoing use for weight maintenance. Both compounds have short half-lives in native form, limiting direct translation from studies. Individual responses vary and no compound replaces standard medical evaluation.","claims":[{"id":"c1","text":"VIP inhalation showed effects in a prospective controlled trial of 8 pulmonary hypertension patients.","section":"What the evidence actually shows","tier":"human","source_ids":["s2"],"source_status":"sourced","why_material":"Provides one of the few direct human VIP administration datasets.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:14:48.277Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"A double-blind placebo-controlled trial of 24 asthma patients documented bronchodilatory effects from a VIP analogue.","section":"What the evidence actually shows","tier":"human","source_ids":["s4"],"source_status":"sourced","why_material":"Documents human physiological response to VIP-related compound.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:14:48.277Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"VIP reduced inflammatory markers in rat collagen-induced arthritis models.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s6"],"source_status":"sourced","why_material":"Illustrates preclinical immune modulation data.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:14:48.277Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"SURMOUNT trials showed 20.9% mean weight reduction in lead-in phase and further maintenance or additional loss with continued tirzepatide versus regain on placebo.","section":"What the evidence actually shows","tier":"human","source_ids":["s9"],"source_status":"sourced","why_material":"Core human efficacy data for metabolic load reduction.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:14:48.277Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"VIP modulates both innate and adaptive immune responses in animal models of inflammatory disease.","section":"What scientists say","tier":"preclinical","source_ids":["s14"],"source_status":"sourced","why_material":"Supports the immune/autonomic layer discussion.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:14:48.277Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s2","type":"pubmed","url":"https://www.jci.org/articles/view/17500","title":"Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension","quote":"We investigated safety and efficacy of VIP inhalation in eight PPH patients...","link_status":"ok","quote_status":"unverified"},{"id":"s4","type":"pubmed","url":"https://www.hippokratia.gr/vasoactive-intestinal-peptide-inhaled-agonists-potential-role-in-respiratory-therapeutics/","title":"Vasoactive Intestinal Peptide Inhaled Agonists","quote":"Twenty four patients were studied in a double blind placebo controlled trial...","link_status":"ok","quote_status":"unverified"},{"id":"s6","type":"other","url":"https://www.hopkinsarthritis.org/arthritis-news/vasoactive-intestinal-peptide-vip-prevents-experimental-arthritis-news-summary-from-johns-hopkins-arthritis/","title":"VIP prevents experimental arthritis","quote":"VIP has a therapeutic effect on an animal model of rheumatoid arthritis.","link_status":"ok","quote_status":"verified"},{"id":"s9","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/38078870/","title":"The SURMOUNT-4 Randomized Clinical Trial","quote":"Participants ... experienced a mean weight reduction of 20.9%. ... overall mean weight reduction from week 0 to 88 was 25.3% for tirzepatide","link_status":"ok","quote_status":"unverified"},{"id":"s14","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC3883350/","title":"Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions","quote":"VIP affects both innate and adaptive immune responses and acts as a major anti-inflammatory factor in animal models","link_status":"ok","quote_status":"verified"}]},"rationale":"","tokens_in":13630,"tokens_out":3210,"cost":0.0250625,"prev_hash":"genesis","hash":"c1b0d4a750a7be9ebfbaf961eefac4d983a933549d043065bdc81f4f7ef3cb34"}],"provenance":[{"ts":"2026-06-29T22:14:49.159Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Vip for Tirzepatide\nSlug: vip-tirzepatide\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"dual_compound\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"vip\",\"name\":\"VIP\"},{\"id\":\"tirzepatide\",\"name\":\"Tirzepatide\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"vip\",\"name\":\"VIP\",\"section_title\":\"Why VIP might help you\",\"layer\":\"immune / autonomic\",\"steps\":[\"**Therefore for you:** If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.\"],\"prose\":\"1. **Therefore for you:** If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.\"},{\"peptide\":\"tirzepatide\",\"name\":\"Tirzepatide\",\"section_title\":\"Why Tirzepatide might help you\",\"layer\":\"metabolic load / body weight\",\"steps\":[\"**What keeps failing:** Same mechanical overload pattern as other GLP-1 contexts at higher body weight.\",\"**What Tirzepatide is studied to do:** Studied for GLP-1/GIP weight loss — load reduction on spine and joints.\",\"**Therefore for you:** If that layer is part of your problem, Tirzepatide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\"],\"prose\":\"1. **What keeps failing:** Same mechanical overload pattern as other GLP-1 c","response":"{\n  \"slug\": \"vip-tirzepatide\",\n  \"title\": \"VIP and Tirzepatide: Layered Evidence on Immune/Autonomic and Metabolic Pathways\",\n  \"body\": \"## What's breaking down\\n\\nDegeneration can occur across multiple layers. One layer involves immune and autonomic signaling, where unchecked inflammation or disrupted nerve-immune communication may slow tissue repair. Another layer involves metabolic load, where excess body weight increases compressive forces on joints and the spine over time. When repair pathways lag behind these breakdown signals, the imbalance can persist. VIP is discussed in the context of the immune/autonomic layer. Tirzepatide is discussed in the context of the metabolic load layer. No single condition is assumed here.\\n\\n## Why VIP might help you\\n\\n1. **What keeps failing:** Immune and autonomic signaling can contribute to ongoing inflammation or poor tissue coordination if that layer is active in your situation.\\n2. **What VIP is studied to do:** VIP targets repair pathways in tissue through immune modulation rather than symptom masking.\\n3. **Therefore for you:** If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.\\n\\n## Why Tirzepatide might help you\\n\\n1. **What keeps failing:** Same mechanical overload pattern as other GLP-1 contexts at higher body weight.\\n2. **What Tirzepatide is studied to do:** Studied for GLP-1/GIP weight loss — load reduction on spine and joints.\\n3. **Therefore for you:** If that layer is part of your problem, Tirzepatide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\\n\\n## How these fit together\\n\\nEach compound above targets a different degeneration layer. Together they are a stack — not five copies of the same mechanism.\\n- VIP → immune / autonomic\\n- Tirzepatide → metabolic load / body weight\\n\\n## What the evidence actually shows\\n\\nVIP human data come mainly from small trials in pulmonary hypertension (one","tokens_in":13630,"tokens_out":3210,"cost":0,"prev":"genesis","hash":"6ed9ec5534b76be094a6f8eb408361934ee23f5ab6af78039b1cad5c579ead48"},{"ts":"2026-07-17T02:43:28.148Z","model":"owner","action":"voxel_divide","prompt":"","input":"vip-tirzepatide","response":"21 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"6ed9ec5534b76be094a6f8eb408361934ee23f5ab6af78039b1cad5c579ead48","hash":"5696a9df9d8ee82052ccbc84df673e9886bbad63780563469ade47787d72a3c2"}],"energy":{"passes":2,"tokens_in":13630,"tokens_out":3210,"tokens_total":16840,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"5696a9df9d8ee82052ccbc84df673e9886bbad63780563469ade47787d72a3c2"},"posted_at":"2026-06-29T21:33:53.332Z","created_at":"2026-06-29T21:33:53.332Z","updated_at":"2026-07-17T02:43:28.148Z","machine":{"shape":"article.machine/v1","slug":"vip-tirzepatide","kind":"article","read":{"human":"https://miscsubjects.com/a/vip-tirzepatide","json":"https://miscsubjects.com/api/articles/vip-tirzepatide","bundle":"https://miscsubjects.com/api/articles/vip-tirzepatide/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":5,"sources":5,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/vip-tirzepatide/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=vip-tirzepatide","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"vip-tirzepatide\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"vip-tirzepatide\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/vip-tirzepatide/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"vip-tirzepatide\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/vip-tirzepatide | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/vip-tirzepatide","json":"/api/articles/vip-tirzepatide","markdown":"/api/articles/vip-tirzepatide/bundle?format=markdown","skill":"/api/articles/vip-tirzepatide/skill","topology":"/api/articles/vip-tirzepatide/topology","versions":"/api/articles/vip-tirzepatide/revisions","invocations":"/api/articles/vip-tirzepatide/invocations"},"editorial_review":null,"editorial_audit":{"slug":"vip-tirzepatide","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"3f88300a5b900b6d620afe1df331256be0d9b45c3249a4f931a7e67d8c2c2d8d"}}}